ArticleBMC endocrine disorders2024
First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Article in BMC endocrine disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2026Pooled it
- Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report.Human vaccines & immunotherapeutics · 2026Article
- Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer.Archives of endocrinology and metabolism · 2026Article
- Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.Current treatment options in oncology · 2026Review
- Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers.European thyroid journal · 2026Observational
- Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer medicine · 2026Review
- The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice.Virchows Archiv : an international journal of pathology · 2026Review
- Targeted therapy in thyroid cancer: molecular alterations and clinical management.Frontiers in endocrinology · 2026Review
- Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer - a case report and review of the literature.Frontiers in oncology · 2026Article
- Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019-2023.European thyroid journal · 2025Article
- Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.European thyroid journal · 2025Article
- Remarkable Response to Chemo-immunotherapy In Anaplastic Thyroid Cancer.JCEM case reports · 2025Article
- Review
- Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers.Current opinion in endocrine and metabolic research · 2024Article
- FN1, a reliable prognostic biomarker for thyroid cancer, is associated with tumor immunity and an unfavorable prognosis.Oncology letters · 2024Article
- Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy.Biomedicines · 2024Article
- Neoadjuvant treatment with lenvatinib and pembrolizumab in aFrontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaplastic thyroid cancer (ATC) is a rare and aggressive neoplasm. We still lack effective treatment options, so survival rates remain very low. Here, we aimed to evaluate the activity of the combination of lenvatinib and pembrolizumab as systemic first-line therapy in ATC.
methodsIn a retrospective analysis, we investigated the activity and tolerability of combined lenvatinib (starting dose 14 to 24 mg daily) and pembrolizumab (200 mg every three weeks) as first-line therapy in an institutional cohort of ATC patients.
resultsFive patients with metastatic ATC received lenvatinib and pembrolizumab as systemic first-line therapy. The median progression-free survival was 4.7 (range 0.8-5.9) months, and the median overall survival was 6.3 (range 0.8-not reached) months. At the first follow-up, one patient had partial response, three patients had stable disease, and one patient was formally not evaluable due to interference of assessment by concomitant acute infectious thyroiditis. This patient was then stable for more than one year and was still on therapy at the data cutoff without disease progression. Further analyses revealed deficient DNA mismatch repair, high CD8
conclusionsThe combination of lenvatinib and pembrolizumab was effective and moderately tolerated in treatment-naïve ATC patients with occasional long-lasting response. However, we could not confirm the exceptional responses for this combination therapy reported before in pretreated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.